Sectors
A man in a blue suit, white dress shirt, and patterned red tie stands in front of a blurred corporate law office background, representing Chicago lawyers.

Jeffrey Simon

Associate

Jeffrey (Jeff) Simon primarily counsels biotechnology, pharmaceutical, and medical device companies on all aspects of obtaining, defending, and enforcing intellectual property rights.

His practice focuses on drafting patent applications, prosecution of U.S. and foreign patent applications, IP strategy and portfolio management, and freedom-to-operate analysis as well as litigation support and infringement analysis. Jeff’s experience covers a wide range of technologies, including vaccine compositions, antibodies, chimeric antigen receptor (CAR) T cells, exosomes, peptides, bioinformatics, gene therapies, and medical devices.

Prior to joining Foley, Jeff worked as a patent attorney for a multinational corporation, collaborating with division and business group managers to ensure that IP strategy and manufacturing aligned with financial objectives and expense targets. He prepared and prosecuted domestic and international patent applications for a wide variety of health care-based technology platforms. He also managed division dockets for foreign and domestic patent and intellectual property matters, prepared appeal briefs before the Patent Trial and Appeal Board (PTAB), conducted freedom-to-operate evaluations, and provided legal support for litigation and pre-litigation evaluations.

During law school, Jeff served as a judicial extern to the Hon. Richard F. Suhrheinrich of the U.S. Court of Appeals for the Sixth Circuit.

A judge’s gavel and scales of justice rest on a courtroom table, symbolizing the pursuit of justice, while blurred people in the background highlight the vital role of law offices and litigation support in legal proceedings.
July 15, 2026

Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus

Two recent Federal Circuit decisions offer complementary guidance on a recurring question in patent law: what must a patent specification disclose to satisfy written description and enablement under 35 U.S.C. § 112 when the claimed invention is the new use of a genus of known compounds or compositions?
July 11, 2025 In the News

Foley Attorneys Assess Critical IP Considerations for Emerging Medical Device Companies

Foley & Lardner LLP attorneys Shabbi Khan, Nate Beaver, Austin Kim, and Jeff Simon authored the Med Device Online article, "Critical Considerations For IP & Patents For Emerging Medical Device Companies."
January 30, 2024 PTAB Trial Insights

Sotera Stipulation Filed After the Patent Owner’s Response Still Deemed Effective

The Patent Trial and Appeal Board (PTAB) recently addressed both the timing requirements and procedures for filing a Sotera stipulation before the Board in, BMW of North America LLC v. Northstar Systems LLC, IPR2023-01017.
A digital illustration of a human brain with multicolored neural networks and nodes, symbolizing neural connections and brain activity—an artistic nod to the intricate thinking behind intellectual property law.
December 11, 2023 Innovative Technology Insights

AI in Health Care: Powering Patient Outcomes

Welcome to AI in Health Care: Powering Patient Outcomes. In this eBook, our contributors examine this intersection through lenses including its impact on merger activity, antitrust enforcement, patent prosecution, and more.
A pipette dispensing liquid onto a petri dish with a colorful DNA sequencing gel pattern in the background, symbolizing innovation and protection—key concerns for intellectual property law experts.
March 22, 2023 Health Care Law Today

Building Biotech with Brains: Strategies for Maximizing Value of AI-Driven Biotechnology Inventions

Harnessing AI to power biotechnology innovations will likely become a cornerstone part of future IP development.